Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression

British Journal of Psychiatry

Volumn 194, Issue 3, 2009, Pages 252-259

  Uher, Rudolf ^a   Maier, Wolfgang ^b   Hauser, Joanna ^c   Marušič, Andrej ^d   Schmael, Christine ^e   Mors, Ole ^f   Henigsberg, Neven ^g   Souery, Daniel ^h   Placentino, Anna ⁱ   Rietschel, Marceila ^e   Zobel, Astrid ^b   Dmitrzak Weglarz, Monika ^c   Petrovic, Ana ^d   Jorgensen, Lisbeth ^f   Kalember, Petra ^g   Giovannini, Caterina ⁱ   Barreto, Mara ^h   Elkin, Amanda ^a   Landau, Sabine ^a   Farmer, Anne ^a   Aitchison, Katherine J ^a   McGuffin, Peter ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BONN   (Germany)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^e CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF ZAGREB   (Croatia)

^h ERASME HOSPITAL   (Belgium)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ESCITALOPRAM; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; BECK DEPRESSION INVENTORY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEXUAL DYSFUNCTION; SUICIDE ATTEMPT; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTRIPTYLINE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62149114432     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.057554     Document Type: Article

References (45)

1. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67: 1836-55.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163, 1905-17.
3. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.
4. Cipriani A, Geddes JR, Furukawa TA, Barbui C. Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice. Can J Psychiatry 2007; 52: 553-62.
5. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000; 2: CD001851.
6. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry 1997; 42: 568-76.
7. Katz MM, Koslow SH, Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 1996; 4: 257-67.
8. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 2163-77.
9. Santor DA, Coyne JC. Examining symptom expression as a function of symptom severity: item performance on the Hamilton Rating Scale for Depression. Psychol Assess 2001; 13: 127-39.
10. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38: 289-300.
11. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005; 30: 445-60.
12. Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 1992; 3: 434-40.
13. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 2002; 47: 262-66.
14. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001; 11: 9-21.
15. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry 2006; 59: 1001-5.
16. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008; 7: 93-106.
17. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310-7.
18. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162: 836-46.
19. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003; 167: 353-62.
20. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467-89.
21. Taylor D, Duncan D. Plasma levels of tricyclics and related antidepressants: are they necessary or useful? Psychiat Bull 1995; 19: 548-50.
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
23. Hamilton M. Development of a rating scale for primary depressive illness, Br J Clin Psychol 1967; 6: 278-96.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiat 1961; 4: 561-71.
25. Thissen D, Chen WH, Bock D. MULTILOG 7. Scientific Software International, 2003.
26. World Health Organization. The ICD-70 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
27. American Psychiatric Association. Diagnostic and statistical Manual of Mental Disorder, (4th edn) (DSM-IV). APA, 1994.
28. Wing JK, Sartorius N, Ustin TB. Diagnosis and Clinical Management in Psychiatry. A Reference Manual for SCAN. World Health Organization, 1998.
29. Little T and Rubin D. Analysis with Missing Data. John wiley & Sons, 1987.
30. StataCorp. Stata statistical software: release 10. Stata Corp LP, 2007.
31. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrac M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatric Res 2000; 34: 3-10.
32. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152-65.
33. Serretti A, Mandelli L, Lorenzi C, Pirovano A, Olgiati P, Colombo C, et al. Serotonin transporter gene influences the time course of improvement of 'core' depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res 2007; 149: 185-93.
34. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr scand 1975; 51: 161-70.
35. Embretson SE, Reise SP. Item Response Theory for Psychologists. Lawrence Erlbaum Associates, 2000.
36. Perlis RH, purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64: 689-97.
37. Davidson J, Turnbull CD. Diagnostic significance of vegetative symptoms in depression. Br J Psychiatry 1986; 148: 442-6.
38. Moller HJ. Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 2001; 251 (suppl 2): II13-20.
39. Serretti A, Cusin C, Benedetti F, Mandelli L, Pirovano A, Zanardi R, et al. insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 137: 36-9.
40. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004; 161: 2045-9.
41. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
42. Leon AC, Marzuk PM, Portera L More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry 1995; 52: 867-71.
43. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test, J Clin Epidemiol 2004; 57: 229-36.
44. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120-7.
45. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002; 36: 384-91.